Jeff Farrow

Jeff has more than 25 years of finance and operational experience within the life science industry. During his career, he was integral in the transition of 3 companies from the clinical development stage to commercial entities and raised more than $2 billion in equity and debt financing. His areas of expertise include leading teams in finance, tax and accounting, information technology (IT), investor relations, corporate communications, facilities, and human resources.

Prior to joining Tarsus, Jeff served as Chief Financial Officer (CFO) at Global Blood Therapeutics, Inc. (GBT), where he played a significant role on the leadership team that secured regulatory approval and successfully commercialized Oxbryta® for the treatment of sickle cell disease. Prior to his time at GBT, Jeff was CFO at ZS Pharma, a company that developed a therapy for the treatment of hyperkalemia before its acquisition by AstraZeneca. Jeff also served as CFO of Hyperion Therapeutics, Inc., a pharmaceutical company that successfully commercialized Ravicti® for the treatment of urea cycle disorders. Earlier in his career, Jeff worked in the audit practice of KPMG LLP. Jeff has also served on the Board of Directors of Clover Biopharmaceuticals, Ltd. since September 2021.

Jeff holds a BA in business administration with a concentration in corporate finance from California State University at Fullerton and is a certified public accountant (inactive).